| Outcome Measures: |
Primary: Number of Participants With Clinically Significant Adverse Effects, Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product., Day 1 through Day 49 | Secondary: Area Under the Concentration Time Curve (AUC), AUC for Day 1 is AUC from 0 to 24 hours. AUC for all other days is AUC at a dosing interval., Predose, 1, 2, 4, 6, 7, 10, 12 and 24 hours Postdose|Maximum Drug Concentration (Cmax), Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose|Time to Maximum Drug Concentration (Tmax), Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose|Number of Hypoglycemic Events, Number of hypoglycemia events with blood glucose concentration \<70 milligram/deciliter (mg/dL)., Day 1 through Day 29
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miramar, Florida, 33025, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, 117597, Singapore
|
